Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Positive top-line results from the pivotal BLUE-C study showed that the next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30% lower false positive rate compared to DeeP-C, the FDA registrational trial for Cologuard.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login